References
- Biberaglu K., Behrman S. J. Hirsutism: diagnostic approach and stimulation-suppression dynamics of androgens in the female. Int. J. Fertil. 1982; 27: 146–52
- Grasinger C. C., Wild R. A., Parker I. J. Vulvar acanthosis nigricans: a marker for insulin resistance in hirsute women. Fertil. Steril. 1993; 59: 583–6
- Norris H. J., Chorlton I. Functioning tumors of the ovary. Clin. Obstet. Gynecol. 1974; 17: 189–228
- Dunaif A., Scully R. E. MGH Case Records (Case 22–1988): a 13-year-old girl with secondary amenorrhea, obesity, acanthosis nigricans, and hirsutism. N. Engl. J. Med. 1988; 318: 1449–57
- Franks S. Polycystic ovary syndrome. N. Engl. J. Med. 1995; 333: 853–61
- Peiris A. N., Aiman E. J., Drucker W. D., Kissebah A. H. The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women. J. Clin. Endocrinol. Metab. 1989; 68: 715–20
- Nestler J. E., Clore J. N., Blackard W. G. The central role of obesity (hyperinsuline-mia) in the pathogenesis of the polycystic ovary syndrome. Am. J. Obstet. Gynecol. 1989; 161: 1095–7
- Bergh C., Carlsson B., Olsson J. H., Selleskog U., Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil. Steril. 1993; 59: 323–31
- Dunaif A., Mandeli J., Fluhr H., Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1988; 66: 131–9
- Toscano V., Bianchi P., Balducci R., Guglielmi R., Mangiantini A., Lubrano C., Sciarra F. Lack of linear relationship between hyperinsulinemia and hyperandrogenism. Clin. Endocrinol. (Oxf.) 1992; 36: 197–202
- Singh A., Hamilton-Fairley D., Koistinen R., Seppala M., James V. H., Franks S., Reed M. J. Effect on insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-1 binding protein I (IBP-I) by human hepatoma cells. J. Endocrinol. 1990; 124: Rl–3
- Jialal I., Naiker P., Reddi K., Moodley J., Joubert S. M. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 1987; 64: 1066–9
- Ciaraldi T. P., el-Roeiy A., Madar Z., Reichart D., Olefsky J. M., Yen S. S. C. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 1992; 75: 577–83
- Dale P. O., Tanbo T., Djoseland O., Jervell J., Abyholm T. Persistance of hyperinsu-linemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist. Acta Endocrinol. (Copenh.) 1992; 126: 132–6
- Dunaif A., Segal K. R., Futterweit W., Dobr-Jansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–74
- Dahlgren E., Janson P. O., Johansson S., Lapi-Udus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective study of women. Acta Obstet. Gynecol. Scand. 1992; 71: 599–604
- Chang R. J., Laufer L. R., Meldrum D. R., De-Fazio J., Lu J. K., Vale W. W., Rivier J. E., Judd H. L. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J. Clin. Endocrinol. Metab. 1983; 56: 897–903
- Steingold K., De Ziegler D., Cedars M., Meldrum D. R., Lu J. K., Judd H. L., Chang R. J. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J. Clin Endocrinol. Metab. 1987; 65: 773–8
- Miller J. A., Jacobs H. S. Treatment of hirsutism and acne with cyproterone acetate. Clin. Endocrinol. Metab. 1986; 15: 373–89
- Couzinet B., Le Strat N., Brailly S., Schaison G. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 1986; 63: 1031–5